Document is current

Article History

Received: 20 October 2024

Accepted: 3 June 2025

First Online: 20 June 2025

Declarations

:

: The following authors declare no Competing Non-Financial Interests but the following Competing Financial interests: Ben Asani receives speaker fees and study support from Novartis AG and a writing Grant from Alcon. Johannes Schiefelbein receives study support from Novartis AG. Tina Herold receives speaker honoraria and study support from Novartis AG and Bayer AG, speaker honoraria from Abbvie, and study support from RocheHolding AG. Jakob Siedlecki receives speaker honoraria and travel reimbursement from Carl Zeiss Meditec AG, Novartis AG, Bayer AG, Pharm-Allergan GmbH, Oculentis OSD Medical GmbH.Consultant: Bayer AG, Novartis AG, Pharm-Allergan GmbH. Travelreimbursement: Oertli AG. Julian Klaas receives speaker fees from Novartis AG. Benedikt Schworm receives Speaker honoraria and travel reimbursement from Novartis AG and Topcon Corporation. Siegfried Priglinger receives speaker and consultant honoraria from and has served on advisory boards for Abbott, Alcon, Geuder, Oculus, Schwind, STAAR, TearLab, Thieme Compliance, Ziemer, Zeiss; has received researchfunding from Abbott, Alcon, Hoya, Oculentis, Oculus, Schwind and Zeiss. Franziska Kruse declares no competing financial or non-financial interests.

: The data was analyzed anonymously using only the surgical catalogue and OPS-codes to acquire statistical data without any conclusion to patient IDs or name. The ethics committee of the Ludwigs-Maximilians-University Munich issued an issue of no objection and the need for approval was waived (Identifier: 24-0776-KB).